Medical Professional Publications

Pharmacy and Therapeutics Committee Updates

(From the January 2015 Issue of MedStat)

For more detailed information, contact Kimberly Novak at Kimberly.Novak@NationwideChildren.org.

The following actions were taken at the November 6 and December 4 Pharmacy & Therapeutics Committee meeting.

Clinic medication stock lists for Primary Care with Teen Clinic: Near East P.C./Eastland P.C./Northland P.C./Westside P.C./Whitehall P.C., Primary Care Red/Primary Care Yellow/Olentangy P.C./Sharon Woods P.C./Mobile Unit/Ronald McDonald Mobile Unit, Hilltop Primary Care/Linden Primary Care, Eye Clinicand Infectious Diseases Clinic were APPROVED.

A Rapid Infliximab (Remicade®) Infusion Protocol was APPROVED for use in GI patients in Infusion clinic. The protocol will be posted in Infusion clinic Policies & Procedures and will be transitioned to electronic view within the NCH Lexi-comp formulary.

RimabotulinumtoxinB (Myobloc®) was APPROVED for formulary addition.  Primary use will be for sialorrhea, spasticity, and failure of botulinum toxin A for various indications.  The monograph will be posted on the P&T intranet website. A review of formulary drug use will be presented in six months.

Clinic medication stock lists for Complex Care Clinic was APPROVED.

The T5A-BHPyxis Override List was APPROVED forthe new Behavioral Health unit scheduled to open 12/10/14.

A Formulary Usage Report was presented on inpatient use of acetaminophen/isometheptene/dichloralphenazone (Midrin®/Nodolor™).  Due to limited use (2 patients encompassing 4 admissions over past 2 years) and high cost/waste due to outdating, acetaminophen/isometheptene/dichloralphenazone (Midrin®/Nodolor™) was REMOVED from formulary.

Insulin glulisine (Apidra®) was APPROVED for formulary addition with the following restriction for use: continuation of home therapy only. The monograph will be posted on the P&T intranet website. A review of formulary drug use will be presented in six months.

Antihemophilic Factor [Recombinant] (Kogenate FS®) Second generation recombinant factor VIII, standard half-life was APPROVED for formulary addition. The monograph will be posted on the P&T intranet website. A review of formulary drug use will be presented in six months.

Antihemophilic Factor [Recombinant] (Recombinate®) First generation recombinant factor VIII, standard half-life was REMOVED from formulary.

Antihemophilic Factor VIII (Recombinant), Fc Fusion Protein (Eloctate®) was APPROVED for formulary addition. The monograph will be posted on the P&T intranet website. A review of formulary drug use will be presented in six months.

Coagulation Factor IX (Recombinant), Fc Fusion Protein (Alprolix®) Extended half-life was APPROVED for formulary addition. The monograph will be posted on the P&T intranet website. A review of formulary drug use will be presented in six months.

The Updated Drug Card: Ketamine – for BRONCHIDILITATION was APPROVED.  It is viewable in the online drug card database.

The Updated Drug Card: Ketamine – for SEDATION and ANESTHESIA was APPROVED.  It is viewable in the online drug card database.

Non-action item:

The Third Quarter 2014 Non-formulary Medication Use Report was presented for informational purposes.

A Vigabatrin REMS Audit summary was presented for informational purposes.  NCH was found to be fully compliant with REMS requirements during the August 2014 onsite audit.

Download myChildren’s FREE mobile app!

Now with Urgent Care Wait Times.
Available for iPhone and Android.

Download the FREE app now »

Nationwide Children's Hospital
700 Children's Drive Columbus, Ohio 43205 614.722.2000